Abstract
Aim: Cabazitaxel is a novel taxane that is approved for use in metastatic castration-resistant prostate cancer based on the Phase III TROPIC study, which showed improved overall survival with cabazitaxel/prednisone versus mitoxantrone/prednisone. A global early-access program was initiated in order to provide early access to cabazitaxel in docetaxel-pretreated patients and to obtain real-world data. Patients & methods: We report interim safety results from an Italian prospective, single-arm, multicenter, open-label trial of 218 patients receiving cabazitaxel 25 mg/m2 every 3 weeks plus prednisolone 10 mg/day, until disease progression, unacceptable toxicity, investigator's decision or death. Results: Patients completing treatment received a median of six cabazitaxel cycles. The most common grade 3/4 adverse events were neutropenia (33.9%), leukopenia (15.6%), anemia (6%) and asthenia (6%). No peripheral neuropathy or nail disorders were observed. Conclusion: These results confirm that cabazitaxel has a manageable safety profile in daily clinical practice and support its use in patients with prostate cancer who progress during or after a docetaxel-based therapy.
Original language | English |
---|---|
Pages (from-to) | 975-983 |
Number of pages | 9 |
Journal | Future Oncology |
Volume | 10 |
Issue number | 6 |
DOIs | |
Publication status | Published - 2014 |
Keywords
- cabazitaxel
- castrate resistant
- docetaxel
- prostate cancer
- safety
- taxane
ASJC Scopus subject areas
- Oncology
- Cancer Research
- Medicine(all)